HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,780 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Follow-Up Questions
HUTCHMED (China) Ltd 'in CEO'su kimdir?
Dr. Weiguo Su 2017 'den beri şirketle birlikte olan HUTCHMED (China) Ltd 'in Chief Executive Officer 'ıdır.
HCM hissesinin fiyat performansı nasıl?
HCM 'in mevcut fiyatı $17.45 'dir, son işlem günde 0% decreased etti.
HUTCHMED (China) Ltd için ana iş temaları veya sektörler nelerdir?
HUTCHMED (China) Ltd Pharmaceuticals endüstrisine ait ve sektör Health Care 'dir
HUTCHMED (China) Ltd 'in mevcut piyasa değerlemesi $2.9B 'dir
HUTCHMED (China) Ltd al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 16 analist HUTCHMED (China) Ltd için analist derecelendirmeleri gerçekleştirdi, bunlar 9 güçlü al, 15 al, 3 tut, 0 sat ve 9 güçlü sat içermektedir
